Skip to content
BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Abpro Holdings, Inc. ABPO

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$-2.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

DiversImmune® is our antibody discovery platform that rapidly generates a diverse collection of proprietary antibodies against both clinically validated and novel targets that have been traditionally difficult to access. This provides us with high affinity and high specificity antibody building blocks with drug-like properties that we then use to engineer novel therapeutics. MultiMab™ is our engineering platform that provides us with the flexibility to combine these antibody building blocks in different combinations and orientations to rapidly create “fit for purpose” novel full-length multi-specific antibody constructs. Our antibody constructs, including our TetraBi antibody format, can potentially benefit patients with the goal of improved efficacy, better safety profiles, and more convenient dosing regimens relative to current standard-of-care therapies.

Written from the business description in Abpro Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2024 · Revenue 0.2 · Net income -7.2
-5M-10M
20222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -5421.3%
-5000%
202220232025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Net buybacks $M Dividends $M
FY2023 · Dividends · · Net buybacks 276.5
100M200M
20222023

Total assetsUSD 1.1M
EquityUSD -8.8M
CashUSD 82,000.00
Current ratio0.10×

Equity funds -831% of total assets.

The 4-year record

4 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ABPO, 4-year financial record
Metric 2025202420232022
Revenue $B◌0.00.0◌
Operating income $B−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0◌
Income tax $B◌◌0.00.0
Net income $B−0.0−0.0−0.00.0
Free cash flow $B◌◌−0.0◌
EPS, diluted $−1.30−22.31−0.61◌
Dividend / sh $◌◌◌◌
Payout % — not applicable: no dividend————
ROE % — not applicable: negative equity————
Shares out B0.000.050.02◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure in 15 reconciliationsAUDITED

Reconciled in 3 of the 4 fiscal years we could check. 30 checks were skipped: the balance sheet is not tagged before 2022. 16 checks were skipped: the share count is not tagged before 2023.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2022

Share this section

Download image